MitoRx Therapeutics is a pre-clinical stage rare disease biotech company which has developed next generation mitochondrial sulfide donor small molecule drugs. Our MoA is the activation of an endogenous mitochondrial protection pathway (first-in-target, first-in-class) which protects mitochondrial function and integrity, nerve cell function, muscle function and mass as well as healthspan.

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE‑A4, -A10, and AFP across several solid tumor indications. The Company is located in Philadelphia, USA and Oxfordshire, U.K.In 2021 Adaptimmune executed a deal with Genentech on proprietary stem-cell derived T-cells worth $300M in cash and over $3B in milestone payments. In 2014, Adaptimmmune entered into a strategic collaboration and licensing agreement worth $350 million (later expanded to $500 Million) with GlaxoSmithKline for the development and commercialisation of the NY-ESO-1 clinical cancer programme. In September 2014, the company completed a $104 million Series A financing round and was listed in the top 15 private biotech firms globally by Fierce Biotech. In 2015 Adaptimmune floated on Nasdaq, raising $191M.

We successfully took our first drug in oncology, the topoisomerase II inhibitor Savene®/Totect® from bench to market in 7 years. This was launched (Europe 2006/US 2007) and sold by our own specialised sales team. Our currently most advanced compound belinostat [Beleodaq(R)] is a histone deacetylase inhibitor and is being investigated in a clinical development program of more than 30 clinical trials in various cancer types, including trials in T-cell lymphoma which led to FDA marketing approval in 2014. Topotarget is headquartered in Denmark and after a successful IPO in 2005 is listed on the OMX Nordic Exchange in Copenhagen (OMX: TOPO). There are subsidiaries in Germany, Switzerland and the UK.Global responsibility for strategic prosecution of all IPR, leveraging IP to extract value for the company. Examples of IP monetization:Spectrum................Oncology...................$350m + royaltiesCuragen..................Oncology...................$51m + royaltiesLEO........................Dermatology..............$43m + royaltiesSpePharm...............Oncology...................$8.2mApricus...................Oncology...................$4m Edimer................... Orphan disease..........$2.4m + royaltiesInhibox....................Inflammation..............UndisclosedMultimeric...............Vaccines...................UndisclosedOncology Venture....Oncology...................UndisclosedInitial Public Offering (2005) ............$39m

CoCo Therapeutics is a UK biotechnology company focussed on the discovery of new drugs for the treatment of Alzheimer’s disease. The company’s programmes are based on the recent scientific discoveries from the laboratory of Professor Jonathan Corcoran at King’s College London, made during research funded by the Wellcome Trust. This research has implicated RAR-alpha, a novel target, in Alzheimer’s disease.

Led programs on anti-cancer drug discovery for inhibitors of hypoxia signalling (acquired by NovusPharma), inhibitors of estrogen receptor signalling (discontinued) and inhibitors of histone deacetylases (acquired by TopoTarget).

Preclinical studies of kinase inhibitors, including Glivec(R), as anti-cancer agents.